Skip to main content
RENERVE LIMITED logo

RENERVE LIMITED — Investor Relations & Filings

Ticker · RNV ISIN · AU0000358616 ASX Manufacturing
Open in API
Filings indexed 134 across all filing types
Latest filing 2026-02-17 Regulatory Filings
Country AU Australia
Listing ASX RNV

About RENERVE LIMITED

https://renerve.com.au/

Renerve Limited is a medical technology company focused on the development and commercialization of advanced solutions for tissue repair and regeneration. The company specializes in peripheral nerve repair through its proprietary NervAlign platform. This technology utilizes a specialized decellularization process to create high-quality nerve grafts derived from porcine tissue. These grafts are designed to provide a natural scaffold that supports and guides axonal regrowth across nerve gaps, offering an alternative to traditional autografts. By maintaining the structural integrity and biochemical cues of the extracellular matrix, Renerve's products aim to improve functional recovery outcomes for patients suffering from traumatic nerve injuries. The company's research and development efforts are centered on expanding the applications of its tissue engineering platform to address various clinical needs in regenerative medicine.

Recent filings

Filing Released Lang Actions
Cleansing notice 3 pages 271.1KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 18 February 2026, titled "NOTICE UNDER SECTION 708A(5)(e) OF THE CORPORATIONS ACT 2001 (CTH)". It notifies the market about the issue of 746,089 fully paid ordinary shares at an issue price of $0.12 per share pursuant to a previous Appendix 2A announcement. The notice references compliance with sections of the Corporations Act related to disclosure exemptions for share issues. The content is regulatory in nature, focused on a capital raising event but does not provide detailed financial data or a full report. It is a formal announcement of a share issue under a specific legal provision, not a full capital/financing update report or an annual/interim report. The document length is just over 5,000 characters but the content is clearly a regulatory announcement about a share issue under section 708A(5)(e). This fits best under the category of Regulatory Filings (RNS) as it is a compliance notice rather than a detailed capital update or financial report.
2026-02-17 English
Proposed issue of securities - RNV 5 pages 17.2KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B - Proposed issue of securities' and contains detailed information about a proposed placement or other type of securities issue by RENERVE LIMITED. It includes specifics such as the number of securities to be issued, the issue date, conditions, and compliance with ASX Listing Rules. This type of document is a formal announcement related to capital raising or changes in capital structure. It is not a financial report, earnings release, or management discussion. The content aligns with announcements about fundraising or capital structure changes, which corresponds to the 'Capital/Financing Update' category.
2026-02-16 English
ReNerve Receives $517k R&D Refund 3 pages 272.9KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 16 February 2026 regarding ReNerve Limited receiving a $517k R&D Tax Incentive Refund. It describes the refund, the company's R&D activities, product portfolio, market growth, and contact information. There are no financial statements, detailed financial performance data, or comprehensive report content. The document is a corporate announcement about a government tax incentive refund, not a full financial report or earnings release. It is not a report publication announcement since it does not mention an attached or forthcoming report. The content fits best as a general regulatory announcement about a financial event (R&D tax refund). Therefore, the most appropriate classification is Regulatory Filings (RNS).
2026-02-15 English
Q2 FY26 Activities Report and Appendix 4C 10 pages 625.5KB
Interim / Quarterly Report Classification · 100% confidence The document is an ASX announcement titled 'Quarterly Activities Report for the Period Ended 31 December 2025' and includes detailed financial and operational information for the quarter ending December 31, 2025 (Q2 FY26). It contains comprehensive financial data such as sales figures, cash flow statements, expenditure breakdowns, and operational highlights. The document also includes forward-looking statements and milestones for the next half-year period. The presence of detailed financial statements and substantive financial data for a period shorter than a full fiscal year clearly identifies this as an Interim / Quarterly Report. It is not merely an announcement of a report or a certification, but a full quarterly report with financial and operational details. Therefore, the correct classification is 'IR' (Interim / Quarterly Report).
2026-01-29 English
Application for quotation of securities - RNV 8 pages 20.9KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Appendix 2A - Application for quotation of securities' and is an official announcement from RENERVE LIMITED regarding the application for quotation of securities on the ASX. It details the number and type of securities to be quoted, issue dates, and issued capital following quotation. The document references previous announcements such as Appendix 3B related to the issue of securities. The content is focused on the application and administrative details for securities quotation rather than financial results, management changes, or other report types. This matches the category of Share Issue/Capital Change filings, which cover announcements regarding new share issues and capital changes. The document length is 6690 characters, which is substantive and contains detailed information about the securities issue and quotation application, not merely a brief announcement or a report publication notice.
2026-01-14 English
Cleansing notice 3 pages 244.3KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 15 January 2026 from ReNerve Limited. It is a notice under section 708A(5)(e) of the Corporations Act 2001 (Cth), which relates to the issuance of new shares without disclosure under Part 6D.2 of the Act. The document details the number of shares issued, the issue price, and compliance with relevant sections of the Act. It is a regulatory announcement about a capital raising event but does not contain financial statements or detailed financial analysis. The document is relatively short (5087 characters) and is a formal notice rather than a full financial report or earnings release. Therefore, it fits best under Capital/Financing Update (CAP) as it updates on company fundraising activities and capital structure changes.
2026-01-14 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.